TIDMRUA
RNS Number : 3079V
RUA Life Sciences PLC
01 December 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR WITHIN THE UNITED
STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR
ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO
ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR
BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK
LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK
MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE
TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED IN THIS
ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF
SUCH INSIDE INFORMATION, AS PERMITTED BY UK MAR. UPON THE
PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW
CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL
THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.
1 December 2023
RUA LIFE SCIENCES PLC
("RUA" or the "Company")
Result of Placing and Subscription
Further to the announcement made on 30 November 2023 regarding a
proposed placing, subscription and retail offer (the "Launch
Announcement"), RUA Life Sciences plc (AIM: RUA.L) is pleased to
announce that, it has conditionally raised gross proceeds of
approximately GBP 4.0 million (before expenses) under the Placing.
In total, 36,363,636 Placing Shares have been conditionally placed
at the Issue Price of 11 pence per share.
In addition, the Directors of the Company have confirmed their
intention to subscribe for an additional 727,272 Subscription
Shares, raising a further GBP 80,000 . As the Company is currently
in a close period under MAR until the publication of its interim
results for the period ended 30 September 2023 (the "Results"), the
Directors are not permitted to enter into a subscription agreement
until after publication of these results (and subject to each not
being in possession of any other unpublished price sensitive
information at such time). Whilst it is expected that the Results
will be published prior to the expected date of Admission, in the
event that the Directors are unable to subscribe prior to that date
(for whatever reason) the Company will apply for admission of the
Subscription Shares to trading on AIM separately and to take effect
following the admission of the Placing Shares and Retail
Shares.
The Issue Price of 11 pence represents a discount of 43.6 per
cent. to the closing middle market price of 19.5 pence per Ordinary
Shares on 29 November 2023, being the last business day prior to
the announcement of the Fundraising.
Cavendish Capital Markets Limited is acting as agent for and on
behalf of the Company in respect of the Placing. The Placing was
undertaken through an accelerated bookbuild process and was
oversubscribed.
The Retail Offer was launched by way of a separate announcement
at 5.51 p.m. on 29 November 2023. A further announcement will be
made on 8 December 2023 announcing the result of the Retail
Offer.
Admission, Settlement and Dealings
Application will be made to the London Stock Exchange for
admission of the New Ordinary Shares to trading on AIM, being the
market of that name operated by the London Stock Exchange ("
Admission ").
It is expected that admission of the New Ordinary Shares will
take place on or around 8.00 a.m. on 19 December 2023 and that
dealings in the New Ordinary Shares on AIM will commence at the
same time.
In addition to the passing of certain Resolutions at the General
Meeting, the Placing and Subscription, are conditional upon, inter
alia, Admission becoming effective. The Placing is not conditional
on the Subscription being completed, nor is any part of the Placing
subject to clawback from the Retail Offer.
Following Admission of the Placing Shares and the Subscription
Shares and assuming the full take up of the Retail Offer, the
Company will have 66,093,887 Ordinary Shares in issue. The New
Ordinary Shares to be issued, when issued, will be fully paid and
will rank pari passu in all respects with the Existing Ordinary
Shares, including the right to receive all dividends and other
distributions declared, made or paid after the date of issue.
A further announcement will be made in relation to total voting
rights in the Company's share capital following the allotment and
issue of the New Ordinary Shares.
The Circular, containing further details of the Fundraising and
notice of the General Meeting to be held on or around 11.00 a.m. on
18 December 2023 to, inter alia, approve the resolutions required
to implement the Fundraising, is expected to be published and
despatched to Shareholders today. Following its publication, the
Shareholder Circular will be available on the Group's website at
www.rualifesciences.com/investor-relations/reports-documents/.
For the purposes of UK MAR, the person responsible for arranging
release of this announcement on behalf of the Company is Bill
Brown, Chairman.
Capitalised terms used in this announcement (this
"Announcement") have the meanings given to them in the Launch
Announcement, unless the context provides otherwise.
Bill Brown, Chairman of Rua Life Sciences plc, said:
"We are grateful for the support of our existing shareholders
and new investors in making this fundraise a success. Following our
change of strategy, the funds will be targeted at accelerating
growth within contract manufacturing; strengthening the Company's
balance sheet to aid the commercialisation phase of its R&D
projects within the Company's vascular graft and HV leaflet
composite; and enabling the Company to demonstrate value across the
portfolio. The Company is as well positioned as it has ever been
with increased visibility on opportunities in the Contract
manufacturing, giving the board confidence that the Company is on
track to meet its objective of doubling the scale of the Contract
Manufacture business in the medium term and testing results of the
Company's novel composite material for the creation of heart valve
leaflets that has produced results that have exceeded our
expectations and is attracting the interest of major players in the
heart valve industry."
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0)1294 317073
Caroline Stretton, Group Managing Director Tel: +44 (0)1294 317073
Cavendish Capital Markets Limited Tel: +44 (0)20 7220 0500
(Nominated Adviser and Broker)
Giles Balleny/Dan Hodkinson (Corporate Finance)
Charlie Combe (ECM)
Michael Johnson (Sales)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROINKKBKBBDBQDN
(END) Dow Jones Newswires
December 01, 2023 02:00 ET (07:00 GMT)
Rua Life Sciences (LSE:RUA)
過去 株価チャート
から 4 2024 まで 5 2024
Rua Life Sciences (LSE:RUA)
過去 株価チャート
から 5 2023 まで 5 2024